BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List

Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS included for the first time XGEVA successfully renewed BeiGene (NASDAQ: BGNE; HKEX:

Related Keywords

Serbia ,Kazakhstan ,Qatar ,Australia ,United Kingdom ,Belarus ,Brazil ,China ,Beijing ,Russia ,Woman ,Bahrain ,Mexico ,New Zealand ,India ,Egypt ,Morocco ,Kuwait ,Ecuador ,Cambridge ,Cambridgeshire ,Switzerland ,Malaysia ,Japan ,Philippines ,Algeria ,Argentina ,Lebanon ,Colombia ,United Arab Emirates ,Canada ,Jordan ,Thailand ,Israel ,Singapore ,Saudi Arabia ,Chile ,Peru ,Turkey ,Dana Yu ,Kevin Mannix ,Gabrielle Zhou ,Xiaobin Wu ,Kyle Blankenship ,Exchange Commission ,Amgen ,National Reimbursement Drug List ,European Union ,York Heart Association Class ,China National Healthcare Security Administration ,National Healthcare Security Administration ,Chief Operating Officer ,General Manager ,License Applications ,Important Safety ,New York Heart Association Class ,Tumor Lysis Syndrome ,Respiratory Distress Syndrome ,Reversible Encephalopathy Syndrome ,Serious Toxicities ,Newly Diagnosed Transplant Ineligible ,Prescribing Information ,Same Active ,Diaphyseal Femoral ,Following Treatment Discontinuation ,Giant Cell Tumor ,Vertebral Fractures ,Following Treatment ,Switzerland Beijing ,Private Securities Litigation Reform Act ,Beigene ,Nnounces ,Expansion ,Coverage ,Ational ,Reimbursement ,Drug ,Mist ,